Literature DB >> 18602691

Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells.

Yana Zhang1, Zhiqing Wang, Jian Zhang, Seah H Lim.   

Abstract

Semenogelin (SEMG) I is a cancer-testis antigen expressed in myeloma cells. SEMG I expression is upregulated by IL-4, IL-6 and 5-azacytidine. In this study, we set out to define the core promoter sequence needed for the expression of SEMG I in myeloma cells. We found that nucleotide sequences spanning the two putative GATA-1 binding domains are vital for the primary regulation of SEMG I promoter function while the other parts of the promoter sequence are responsible for the fine adjustment of the core promoter function. The core promoter sequence is responsive to the enhancing effect of IL-4 and IL-6.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602691      PMCID: PMC2605945          DOI: 10.1016/j.leukres.2008.05.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

1.  Gene structure of semenogelin I and II. The predominant proteins in human semen are encoded by two homologous genes on chromosome 20.

Authors:  M Ulvsbäck; C Lazure; H Lilja; N K Spurr; V V Rao; C Löffler; I Hansmann; A Lundwall
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

2.  Semenogelin I expression in myeloma cells can be upregulated pharmacologically.

Authors:  Yana Zhang; Zhiqing Wang; Jian Zhang; Benjamin Farmer; Seah H Lim
Journal:  Leuk Res       Date:  2008-05-12       Impact factor: 3.156

3.  Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa.

Authors:  H Lilja; P A Abrahamsson; A Lundwall
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

4.  Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes.

Authors:  F A Asimakopoulos; N J White; E Nacheva; A R Green
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

5.  Semenogelin, the main protein of semen coagulum, inhibits human sperm capacitation by interfering with the superoxide anion generated during this process.

Authors:  E de Lamirande; K Yoshida; T M Yoshiike; T Iwamoto; C Gagnon
Journal:  J Androl       Date:  2001 Jul-Aug

6.  Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies.

Authors:  Yana Zhang; Zhiqing Wang; Haichao Liu; Francis J Giles; Seah H Lim
Journal:  J Immunother       Date:  2003 Nov-Dec       Impact factor: 4.456

7.  Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues.

Authors:  Ake Lundwall; Anders Bjartell; A Yvonne Olsson; Johan Malm
Journal:  Mol Hum Reprod       Date:  2002-09       Impact factor: 4.025

8.  Characterization of semenogelin proteins in the human retina.

Authors:  Vera L Bonilha; Mary E Rayborn; Karen Shadrach; Ake Lundwall; Johan Malm; Sanjoy K Bhattacharya; John W Crabb; Joe G Hollyfield
Journal:  Exp Eye Res       Date:  2006-03-20       Impact factor: 3.467

  8 in total
  4 in total

1.  Seminal plasma protein in renal cell carcinoma: expression of semenogelin I is a predictor for cancer progression and prognosis.

Authors:  Shengli Zhang; Jianzheng Fang; Xiangxiang Zhang; Chao Qin; Shifeng Su; Yunfei Deng; Zhen Song; Yi Zhang; Hainan Wang; Changjun Yin; Zengjun Wang
Journal:  Tumour Biol       Date:  2014-06-11

2.  Cancer-testis antigens: the current status on antigen regulation and potential clinical use.

Authors:  Seah H Lim; Yana Zhang; Jian Zhang
Journal:  Am J Blood Res       Date:  2012-01-01

3.  O-GlcNAc homeostasis contributes to cell fate decisions during hematopoiesis.

Authors:  Zhen Zhang; Matthew P Parker; Stefan Graw; Lesya V Novikova; Halyna Fedosyuk; Joseph D Fontes; Devin C Koestler; Kenneth R Peterson; Chad Slawson
Journal:  J Biol Chem       Date:  2018-12-06       Impact factor: 5.157

4.  Identification of Urinary Biomarkers for Exercise-Induced Immunosuppression by iTRAQ Proteomics.

Authors:  Guoqin Xu; Wentao Lin; Andrew J McAinch; Xu Yan; Xiquan Weng
Journal:  Biomed Res Int       Date:  2020-01-23       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.